menu
    • menu
    [{"orgOrder":0,"company":"Pharmanovia","sponsor":"Aquestive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Pharmanovia \/ Pharmanovia"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Pharmanovia","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Pharmanovia \/ Pharmanovia"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Closed Loop Medicine","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"4","companyTruncated":"Pharmanovia \/ Pharmanovia"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Stealth Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Elamipretide","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"10","companyTruncated":"Pharmanovia \/ Pharmanovia"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Clobazam","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Pharmanovia \/ Pharmanovia"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Lindus Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chloral Hydrate","moa":"","graph1":"Sleep","graph2":"Phase IV","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Pharmanovia \/ Lindus Health","highestDevelopmentStatusID":"11","companyTruncated":"Pharmanovia \/ Lindus Health"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Pharmanovia \/ Pharmanovia"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Lindis Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Catumaxomab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"10","companyTruncated":"Pharmanovia \/ Pharmanovia"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Lindis Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"CD3\/EpCAM","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Pharmanovia \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Pharmanovia \/ Pharmanovia"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmanovia

    Menu

    Pharmanovia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Lindis Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lindis, Pharmanovia Secure EU Approval for Catumaxomab in Malignant Ascites

                            Details : Upon authorization by the European Commission, KORJUNY will be the only approved drug for malignant ascites in adults with epithelial cell adhesion molecule (EpCAM)-positive carcinomas

                            Product Name : Korjuny

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Lindis Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Lindis Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmanovia In-Licenses Catumaxomab for Malignant Ascites from Lindis Biotech

                            Details : The agreement gives Pharmanovia the exclusive rights to market, Korjuny (catumaxomab), a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for malignant ascites in adults.

                            Product Name : Korjuny

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 19, 2024

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Lindis Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : CSL

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease

                            Details : Pharmanovia will take over rights from CSL and will be responsible for all commercial and regulatory activities of Xadago (safinamide), for adult patients with idiopathic Parkinson's disease.

                            Product Name : Xadago

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : CSL

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloral Hydrate

                            Therapeutic Area : Sleep

                            Study Phase : Phase IV

                            Sponsor : Lindus Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmanovia Study Shows Chloral Hydrate Improves Severe Insomnia Within Two Weeks

                            Details : Chloral hydrate is converted rapidly to trichloroethanol, which is largely responsible for its hypnotic action. It is indicated for the treatment for severe insomnia.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 01, 2024

                            Lead Product(s) : Chloral Hydrate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase IV

                            Sponsor : Lindus Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi

                            Details : Pharmanovia expands its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from Sanofi, including Frisium (clobazam), Gardenal (phenobarbital), Tercian (cyamemazine), Stemetil, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, N...

                            Product Name : Frisium

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 18, 2023

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elamipretide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Stealth Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipreti...

                            Details : Pharmanovia will commercialize MTP-131 (elamipretide), an investigational mitochondrial protective agent, in Europe for the treatment of Barth syndrome, an ultra-rare cardiac condition caused by mitochondrial cardiolipin deficiency for which there are no...

                            Product Name : MTP-131

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : Elamipretide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Stealth Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Recipient : Closed Loop Medicine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Closed Loop Medicine and Pharmanovia Enter a Co-Development Partnership for Precision Medicine Combination The...

                            Details : Under the partnership, Closed Loop’s proprietary Software-as-a-Medical Device dosing optimization technology will be combined with Pharmanovia’s established anti-hypertensive medicines to develop drug + software product solutions for the treatment of...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Recipient : Closed Loop Medicine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Recipient : Axsome Therapeutics

                            Deal Size : $167.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Dev...

                            Details : Under the agreement, Pharmanovia will be responsible for the development and marketing of Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults with EDS due to narcolepsy or OSA, in Eur...

                            Product Name : Sunosi

                            Product Type : Small molecule

                            Upfront Cash : $66.0 million

                            February 22, 2023

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Recipient : Axsome Therapeutics

                            Deal Size : $167.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pharmanovia

                            United Kingdom arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pharmanovia

                            United Kingdom arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Aquestive Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal...

                            Details : Libervant™ is a buccally, administered film formulation of diazepam, intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from patient’s usual seizure pattern in patients with epilepsy ...

                            Product Name : Libervant

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 28, 2022

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Aquestive Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth